





Fri, 09 September 2022 09:00 – 10:30	Biologics: From then to now Chairs: Marla Dubinsky (USA), Anne Griffiths (Canada)	90 min
09:00 – 09:25	TDM for all biologics?	Amit Assa (Israel)
09:25 – 09:50	What is the role for dual biologic therapy in PIBD?	Marina Aloi (Italy)
09:50 – 10:15	What do head to head biological trials teach us?	Dan Turner (Israel)
10:15 – 10:30	Panel discussion plus Q&A	





ri, 09 September 1022 1:00 – 12:30	Monogenic IBD: mechanisms to therapy Chairs: Holm Uhlig (United Kingdom), Frank Ruemmele (France)	90 min
1:00 – 11:25	Case-based introduction to monogenic IBD issues	Aleixo Muise (Canada)
1:25 – 11:50	Treatment differences between Monogenic IBD, VEOIBD and PIBD	Holm Uhlig (United Kingdom)
1:50 – 12:15	Immune dysregulation and epithelial defects in monogenic IBD	Bernice Lo (Qatar)
2:15 – 12:30	Panel discussion plus Q&A	
3		
matter body	gh International Conference Centre · www.pibdcongress.org	

Fri, 09 September 2022 11:00 – 12:30	Outcomes in IBD – wanted and unwanted Chairs: Lissy de Ridder (The Netherlands), Eric Benchimol (Canada)	90 min
11:00 – 11:20	Have PIBD outcomes really improved in the last 20 years? Population analyses	Ola Olén (Sweden)
11:20 – 11:40	PIBD cancer risk: disease or drug	Eytan Wine (Canada)
11:40 – 12:00	Managing infectious risk in PIBD	Javier Martín de Carpi (Spain)
12:00 – 12:20	Management of VTE risk in PIBD	Michael Kappelman (USA)
12:20 - 12:30	Panel discussion plus Q&A	
Edinbur	gh International Conference Centre · www.pibdcongress.org	13





Advances in clinical trials Chairs: Richard Russell (United Kingdom), Anne Griffiths (Canada)	80 min
Innovations in IBD trial design	Nicholas Croft (United Kingdom)
Designing and running large PIBD trials: lessons learnt	Frank Ruemmele (France)
Industry perspectives	Wallace Crandall (USA)
How to extrapolate for dosing	Robert Skip Nelson (USA)
	Chairs: Richard Russell (United Kingdom), Anne Griffiths (Canada)  Innovations in IBD trial design  Designing and running large PIBD trials: lessons learnt  Industry perspectives

Fri, 09 September 2022 15:55 – 17:15	The IBD holistic approach Chairs: Javier Martin de Carpi (Spain), Kat Armstrong (United Kingdom)	60 min
15:55 – 16:15	Functional issues in IBD	Lissy de Ridder (The Netherlands)
16:15 – 16:35	Are growth issues still a priority in 2022?	Johan van Limbergen (The Netherlands)
16:35 - 16:55	Where do patient priorities differ from clinical teams?	Lisa Gervais (United Kingdom)
16:55 – 17:15	Psychosocial burden	Lyndsay Hughes (United Kingdom)
		Iniiguoiii)
-		





Fri, 09 September 2022 15:55 – 17:15	Improving IBD monitoring Chairs: Dror Shouval (Israel), Iain Chalmers (United Kingdom)	80 min
5:55 – 16:15	Home-based monitoring and treatment	Patrick van Rheenen (the Netherlands)
16:15 – 16:45	USS, MRI and WCE in PIBD: which way forward?	Peter Lewindon (Australia)
16:45 – 17:15	Monitoring PIBD needs a strong Radiology and GI MDT – tandem talk	Simon McGurk and Paul Henderson (United Kingdom)

Fri, 09 September 17:15 – 17:45	Best Oral Presentations Chairs: David Wilson (United Kingdom), Konstantinos Gerasimidis (United Kingdom)	30 min
17:15 – 17:25	Best oral Presentation	
17:25 – 17:35	Best oral Presentation	
17:35 – 17:45	Best oral Presentation	
- [W]		





Fri, 09 September2 022 17:45 – 18:15	State of the art talks Chairs: David Wilson (United Kingdom), Konstantinos Gerasimidis (United Kingdom)	30 min
17:45 – 18:15	Therapies in the IBD pipeline	Charlie Lees (United Kingdom)
-		